middle.news
Chimeric Therapeutics Sees Tumour Shrinkage in Early CHM CDH17 Trial Results
8:38am on Monday 29th of September, 2025 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Sees Tumour Shrinkage in Early CHM CDH17 Trial Results
8:38am on Monday 29th of September, 2025 AEST
Key Points
Dose Level 2 deemed safe by Safety Monitoring Committee
Tumour shrinkage between 12-37% observed in colorectal and neuroendocrine cancer patients
One patient maintains stable disease over 10 months post single dose at Dose Level 1
No off-target effects or gastrointestinal toxicity reported
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE